Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2023.03.03.531049

ALOX15, a new potential functional target of lung adenocarcinoma

Liu, x.·tang, y.·Liu, H.·Zhang, S.·Xuan, s.·Su, y.
View original source ↗Export metadata ↓

Abstract

PurposeThe purpose of this study is to explore whether the down-regulation of ALOX15 is related to the stage, differentiation and prognosis of lung adenocarcinoma, whether the overexpression of ALOX15 can inhibit tumor proliferation and metastasis, and whether it is related to the functional target of lung adenocarcinoma(LUAD). MethodsFirstly, bioinformatics of lung cancer patients was analyzed using the TCGA database to study the differential expression of ALOX15 in LUAD and its effect on the survival of LUAD. Then, 50 clinical tissue samples of LUAD were collected to detect the expression of ALOX15 and its relationship with the differentiation degree and stage of lung cancer. Finally, the relationship between the expression of ALOX15 and the proliferation and differentiation of LUAD cell lines (NCI-H1944, A549, PC9) with different degrees of differentiation and the construction of ALOX15 overexpression stable lines was detected. ResultsALOX15 bioinformatics analysis showed that ALOX15 decreased significantly in the early stage of LUAD and had no correlation with the survival of lung cancer patients. ALOX15 was downregulated in LUAD with low differentiation and metastasis in LUAD. LUAD cell lines showed that the lower the degree of differentiation, the lower the expression of ALOX15, and the overexpression of ALOX15 in LUAD cells inhibited the proliferation and migration of cancer cells. ConclusionThese results suggest that the expression of ALOX15 is closely related to the differentiation, proliferation, and metastasis of LUAD, and that upregulation of ALOX15 may inhibit the development of LUAD, suggesting that ALOX15 is a potential biological therapeutic target. Author summaryO_ST_ABSWhy was this study done?C_ST_ABSO_LILung cancer is one of the most frequently diagnosed cancers in the world and the leading cause of cancer-related deaths worldwide. C_LIO_LILung cancer is a heterogeneous disease with a wide range of clinicopathologic features. Lung cancer is roughly divided into non-small cell lung cancer (85% of all diagnoses) and small cell lung cancer (15% of all diagnoses). Adenocarcinoma is a common subtype of non-small cell lung cancer, and its recurrence rate is high, and the prognosis is poor. Therefore, the pathogenesis and characteristics of adenocarcinoma are studied and explored. C_LI What did the researchers do and find?O_LIBiological information database was used to analyze the expression level of arachidonic acid-15-lipoxygenase (ALOX15) in lung adenocarcinoma, and then the expression differences were discussed through clinical samples and cell experiments. C_LIO_LILow ALOX15 expression was detected in lung adenocarcinoma (LAUD) patients compared with normal tissues, and ALOX15 levels influenced LUAD development. C_LIO_LIBy infecting A549 with lentivirus and overexpressing ALOX15 of A549 and PC-9 with PC9, it was found that ALOX15 inhibited the proliferation of tumor cells C_LI What do these findings mean?O_LIarachidonic acid-15-lipoxygenase may be one novel potential biomarker for LUAD and a potential therapeutic target C_LI

Explore related subjects

cancer biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Liu, x., tang, y., Liu, H., Zhang, S., Xuan, s., Su, y.. 2023-03-06. ALOX15, a new potential functional target of lung adenocarcinoma. https://doi.org/10.1101/2023.03.03.531049

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Tet2-Clonal Hematopoiesis Promotes Whereas Dnmt3a-CH Inhibits Breast Cancer Progression During Aging

Clonal hematopoiesis of indeterminate potential (CHIP) driven by somatic mutations in blood cells increases with age and is associated with adverse outcomes in cancer patients. How CHIP mutations influence solid tumor progression remains unclear. Using inducible murine models of Dnmt3a- or Tet2-mutant CHIP combined with orthotopic syngeneic breast cancer models, we demonstrate that upon aging Dnmt3a-mutant CHIP prevents whereas Tet2-mutant CHIP drives breast cancer progression. Dnmt3a-mutant immune infiltrates established interferon-mediated MHCIIhigh tumor-associated macrophages (TAMs) that supported cytotoxic CD8+ T cell-mediated tumor rejection. In contrast, Tet2-mutant TAMs exhibited an inflammatory, immunosuppressive phenotype characterized by increased IL-1 and CXCL2 production, reduced MHCII expression, and impaired T cell recruitment and activation. Therapeutic blockade of IL-1R1 or CXCR2 reduced tumor progression in aged Tet2-mutant CHIP mice and partially restored anti-tumor immunity. These findings establish that the effects of CHIP on cancer are mutation- and age-dependent and identify IL-1/CXCL2-driven inflammation as a therapeutic vulnerability of tumor-promoting Tet2-mutant CHIP.

cancer biology↗
bioRxiv2026

Single Nucleus Profiling Reveals Rewired Tumor-Immune-Stromal Cell Communication in Plasmacytoid Urothelial Carcinoma

Plasmacytoid urothelial carcinoma (PUC) is an aggressive histologic subtype of bladder cancer associated with worse patient outcomes and therapeutic response compared to conventional urothelial carcinoma (CUC). While recent work has demonstrated metastatic lymph nodes from PUC tumors have an inflamed phenotype, how the tumor microenvironment (TME) and crosstalk between tumor, stromal, and immune cells in primary PUC bladder tumors differs from those in CUC remains poorly understood. The impact of these differences on response to immunotherapy is also unknown. To understand TME differences between CUC and PUC and their impact on cell signaling, we performed single nucleus RNA sequencing on PUC and CUC tumors, as well as Xenium spatial transcriptomics on a mixed CUC / PUC tumor. We identified increased signaling between PUC-enriched, CDH1-low urothelial cells, immunosuppressive lipid-associated macrophages, and SFRP2+/CTHRC1+ fibroblasts in PUC tumors compared to CUC. Spatial transcriptomics identified increased macrophage infiltration in PUC histology and colocalization of PUC tumor cells, immunosuppressive macrophages, and SFRP2+ fibroblasts. Taken together, this study delineates PUC architecture and demonstrates interplay CDH1-low tumor cells, EMT, and immunosuppressive macrophages, identifying possible therapeutic vulnerabilities in PUC.

cancer biology↗
bioRxiv2026

The Phospholipase A2 Activity of Peroxiredoxin 6 Protects Hepatocarcinoma Cells Against Ferroptosis and Mitophagy Impairment

Peroxiredoxin 6 (PRDX6) is a moonlighting protein that plays a key role in regulating redox homeostasis and lipid metabolism through its unique dual peroxidase and calcium-independent phospholipase A2 (iPLA2) activities. Here, we generated a stable HepG2 cell line harboring a D140A mutation to selectively ablate iPLA2 activity, and we compared its phenotype with that of wild-type (WT) and PRDX6-knockout (KO) cells. D140A exhibited low ROS leves, similar to WT cells, confirming that oxidative stress is due to peroxidase deficiency. In contrast, D140A cells displayed higher lipid peroxidation than WT cells, though significantly lower than that of KO cells. Furthermore, the D140A mutant mirrored the KO phenotype regarding intracellular ferrous iron accumulation, impaired lipid droplet biogenesis, and the downregulation of the key ferroptosis regulator GPX4. Mechanistically, integrated proteomic, lipidomic, and enzymatic analyses revealed that a deficiency in iPLA2 activity of PRDX6 disrupted the release of key lipid species necessary for cell structure and signaling. Consequently, organelles involved in lipid synthesis and trafficking, such as peroxisomes, endoplasmic reticulum, mitochondria and lipid droplet, were affected. Specifically, we found that mitochondria exhibited a reduction in cristae and a diminished capacity for mitophagy and autophagy, which ultimately makes cells much more susceptible to erastin-induced ferroptotic cell death. Taken together, our findings demonstrate that PRDX6 iPLA2 activity uniquely coordinates organelle lipid homeostasis and mitophagy to protect cancer cells from ferroptotic cell death. Consequently, the use of iPLA2 inhibitors such as MJ33, which decreased PRDX6 iPLA2 activity to a level comparable to the mutant D140A, could represent a promising therapeutic strategy for inducing ferroptotic cell death in hepatocellular carcinoma.

cancer biology↗